DelveInsight’s “Atopic Dermatitis – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Atopic Dermatitis Overview
Atopic Dermatitis, or atopic eczema, is a type of skin inflammation (dermatitis). It results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, often thickening over time. While the condition may occur at any age, it typically starts in childhood with changing severity over the years. In children under one year of age, much of the body may be affected. As children age, the back of the knees and the front of the elbows are the most common areas affected. In adults, the hands and feet are the most commonly affected areas. Scratching worsens symptoms, and affected people have an increased risk of skin infections. Many people with atopic dermatitis develop hay fever or asthma. The word “atopic” indicates an association with allergies. While atopic dermatitis is not always due to an allergic reaction, it is commonly associated with other allergic disorders: up to 60 percent of people with atopic dermatitis develop asthma or hay fever (allergic rhinitis) later in life, and up to 30 percent have food allergies. The unknown cause involves genetics, immune system dysfunction, environmental exposures, and skin permeability difficulties. If one identical twin is affected, there is an 85% chance the other also has the condition. Those who live in cities and dry climates are more commonly affected. Exposure to certain chemicals or frequent hand washing makes symptoms worse. While emotional stress may make the symptoms worse. The disorder is not contagious. The diagnosis is typically based on the signs and symptoms.
Atopic Dermatitis Epidemiology Insights
-
As per the National Eczema Association 2019, Atopic dermatitis (AD) is the most common type of eczema. In fact, more than 18 million American adults have atopic dermatitis, which often appears as a red, itchy rash normally on the cheeks, arms, and legs.
-
A disease burden study was conducted by Eckert et al. (2019) on European adult patients with Atopic Dermatitis, and the data was collected from the 2016 National Health and Wellness Survey conducted in France, Germany, Italy, Spain, and the United Kingdom. Most respondents, with or without a diagnosis of Atopic Dermatitis, were from Spain (37.0%), followed by Italy (24.6%), France (19.0%), Germany (10.6%), and the United Kingdom (8.9%). Most patients (69.3%) were women, and their mean age was 44 years.
Click here to learn more about the Atopic Dermatitis Market Landscape
The Report Covers the Atopic Dermatitis Epidemiology Segmented by:
-
Atopic Dermatitis prevalent cases
-
Atopic Dermatitis diagnosed prevalent cases
-
Atopic Dermatitis severity-specific distribution
-
Atopic Dermatitis gender-specific prevalent cases
Atopic Dermatitis Market Outlook
The treatment of Atopic Dermatitis aims to reduce the duration, severity, and frequency of disease exacerbations. It is implemented step-wise according to disease severity (mild, moderate, or severe). Off-label treatment, especially systemic immunosuppressants and systemic (oral and injectable) corticosteroids, are frequently prescribed for patients unresponsive to topical therapy. Systemic corticosteroids are indicated for short-term treatment of acute severe Atopic Dermatitis.
Optimal Atopic Dermatitis management includes topical corticosteroids (TCs) as the first-line treatment for Atopic Dermatitis flare-ups. The potencies of these topical corticosteroids range from group I, which is most potent (e.g., clobetasol [Temovate]), through group VII, which is least potent (e.g., hydrocortisone 1%). However, TCS has various side effects and is not recommended for long-term use. The principal complication of prolonged application of topical corticosteroids, especially those of higher potency, is skin atrophy. Other local complications include telangiectasia, striae, hypopigmentation, and corticosteroid acne.
Key Companies Working in the Atopic Dermatitis Market
-
Sanofi
-
Regeneron Pharmaceuticals
-
Pfizer
-
Japan Tobacco and Torii Pharmaceutical
-
Eli Lilly and Company
-
AbbVie
-
LEO Pharma
-
Incyte Corporation
-
Arena Pharmaceuticals
And many others
Atopic Dermatitis Therapies Covered and Analyzed in the Report:
-
Dupixent
-
Eucrisa
-
Olumiant
-
Corectim Ointment
-
Rinvoq
-
Cibinqo
-
Adtralza
-
Opzelura
And many others
Learn more about the Key Companies and Emerging Therapies in the Atopic Dermatitis Market.
Table of Contents
-
Key Insights
-
Atopic Dermatitis Introduction
-
Executive Summary of Atopic Dermatitis
-
Disease Background and Overview
-
Epidemiology and patient population
-
Atopic Dermatitis Emerging Therapies
-
Atopic Dermatitis Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ Atopic Dermatitis Market Outlook.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services